文献速递脑血管病

依达拉奉早期用于血管内再灌注治疗急性缺血性卒中的临床效果

Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy.
PubMed 文献 · Stroke · 2019-01-01

该研究基于日本全国行政数据库开展回顾性观察,纳入11 508例接受急诊血管内再灌注治疗的急性缺血性卒中患者,按入院2天内是否使用依达拉奉分组。经病例组合校正及倾向评分匹配分析,依达拉奉使用与出院时功能独立更高、院内死亡更低及入院后颅内出血更少相关。

要点

  • 接受血管内再灌注治疗的急性缺血性卒中患者中,89.3%在入院2天内使用了依达拉奉。
  • 依达拉奉组出院时功能独立为32.3%,对照组为25.9%,校正OR为1.21(95%CI 1.03-1.41)。
  • 依达拉奉组院内死亡为9.9%,对照组为17.4%;入院后颅内出血为1.4%对2.7%。

核心结论

  • 回顾性分析提示,依达拉奉联合血管内再灌注治疗可能是急性缺血性卒中有前景的治疗策略。
  • 上述结果来自观察性数据,仍需进一步随机对照试验验证。

研究设计与样本

  • 采用日本全国行政数据库开展回顾性观察性研究。
  • 纳入接受急诊血管内再灌注治疗的急性缺血性卒中患者,共11 508例符合分析条件。
  • 按入院2天内是否使用依达拉奉将患者分为两组。

主要发现

  • 依达拉奉组出院时功能独立为32.3%,对照组为25.9%,校正OR为1.21(95%CI 1.03-1.41)。
  • 依达拉奉组院内死亡为9.9%,对照组为17.4%,校正OR为0.52(95%CI 0.43-0.62)。
  • 依达拉奉组入院后颅内出血为1.4%,对照组为2.7%,校正OR为0.55(95%CI 0.37-0.82)。
  • 倾向评分匹配分析结果与上述结果一致。

关键数值与推荐

  • 11 508例中10 281例(89.3%)接受依达拉奉治疗。
  • 风险校正模型对出院时功能独立的预测AUC为0.74。

临床怎么用

  • 在血管内再灌注治疗的急性缺血性卒中患者中,早期使用依达拉奉或可改善出院功能结局并降低院内死亡与颅内出血风险。
  • 该结论基于回顾性数据库分析,临床决策需结合随机对照试验证据与个体情况。

局限性

  • 研究为回顾性观察性设计,存在残余混杂可能。
  • 数据来源于日本全国行政数据库,结论外推需谨慎。
  • 原文指出仍需进一步随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Although several clinical studies suggested the beneficial effects of edaravone in acute ischemic stroke, most were performed under settings that differ from those in the current treatment strategy, which has dramatically changed with progress in reperfusion therapies. This study aimed to evaluate the efficacy of edaravone in patients with acute ischemic stroke treated by emergent endovascular reperfusion therapy. Methods- We conducted a retrospective observational study using a national administrative database. Patients with acute ischemic stroke treated by emergent endovascular reperfusion therapy were identified and dichotomized by whether edaravone was used within 2 days of admission. We compared the functional independence at hospital discharge, in-hospital mortality, and intracranial hemorrhage after admission between groups, adjusted by a well-validated case-mix adjustment model, in multivariate mixed-effect regression and propensity score matching analyses. Results- Of 11 508 patients eligible for analysis, 10 281 (89.3%) received edaravone therapy. The established risk adjustment model had good predictability for functional independence at hospital discharge, with an area under the receiver operating characteristic curve of 0.74. In the mixed-effect regression analysis, edaravone use was significantly associated with greater functional independence at hospital discharge (32.3% in the edaravone group versus 25.9% in the control group; adjusted odds ratio, 1.21; 95% confidence interval, 1.03-1.41), lower in-hospital mortality (9.9% in the edaravone group versus 17.4% in the control group; adjusted odds ratio, 0.52; 95% confidence interval, 0.43-0.62), and reduced intracranial hemorrhage after admission (1.4% in the edaravone group versus 2.7% in the control group; adjusted odds ratio, 0.55; 95% confidence interval, 0.37-0.82). Results of the propensity score matching analysis corroborated these results. Conclusions- This retrospective analysis of a Japanese nationwide administrative database suggested that combination therapy with edaravone and endovascular reperfusion therapy could be a promising therapeutic strategy in acute ischemic stroke. Further randomized control trials are warranted.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Enomoto M, Endo A, Yatsushige H, et al. Clinical Effects of Early Edaravone Use in Acute Ischemic Stroke Patients Treated by Endovascular Reperfusion Therapy. Stroke. 2019. PMID: 30741623. doi:10.1161/STROKEAHA.118.023815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。